MedTrace Logo

Prostatic Acid Phosphatase (PAP) Vaccine in Patients With Prostate Cancer

NCT00582140 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2019-11-19

No results posted yet for this study

Summary

The investigators are trying to find new methods to treat prostate cancer. The approach they investigators are taking is to try to enhance patients own immune response against the cancer. In this study the investigators will be testing the safety of a vaccine that may be able to help the body fight prostate cancer.

Conditions

Interventions

BIOLOGICAL

pTVG-HP with rhGM-CSF

pTVG-HP (dose 1: 100 μg) with rhGM-CSF (200 μg); administered i.d. biweekly for 6 total doses

BIOLOGICAL

pTVG-HP with rhGM-CSF

pTVG-HP (dose 2: 500 μg) with rhGM-CSF (200 μg); administered i.d. biweekly for 6 total doses

BIOLOGICAL

pTVG-HP with rhGM-CSF

pTVG-HP (dose 3: 1,500 μg) with rhGM-CSF (200 μg); administered i.d. biweekly for 6 total doses

Sponsors & Collaborators

  • United States Department of Defense

    collaborator FED

  • University of Wisconsin, Madison

    lead OTHER

Principal Investigators

  • Douglas McNeel, MD · University of Wisconsin, Madison

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-03-31
Primary Completion
2008-08-31
Completion
2008-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00582140 on ClinicalTrials.gov